Search

Your search keyword '"Majin, Castillo"' showing total 22 results

Search Constraints

Start Over You searched for: Author "Majin, Castillo" Remove constraint Author: "Majin, Castillo"
22 results on '"Majin, Castillo"'

Search Results

1. Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study

2. Evaluation of the Relationship Between Serum Urate Levels, Clinical Manifestations of Gout, and Death From Cardiovascular Causes in Patients Receiving Febuxostat or Allopurinol in an Outcomes Trial

3. Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase <scp>III</scp> Placebo‐Controlled Study

4. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout

6. Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study

7. Exploring the use of adalimumab for patients with moderate Crohn's disease: Subanalyses from induction and maintenance trials

8. Association of baseline C-reactive protein and prior anti-tumor necrosis factor therapy with need for weekly dosing during maintenance therapy with adalimumab in patients with moderate to severe Crohn's disease

9. Long-term Effectiveness of Adalimumab in Crohnʼs Disease: Observational Data from the PYRAMID Registry

10. PTU-111 Baseline C reactive protein is associated with disease progression in patients with Crohn's disease: Abstract PTU-111 Table 1

12. Mo1219 Adalimumab Achieves Efficacy in Mucosal Healing Regardless of Baseline Disease Severity in Patients With Crohn's Disease: Data From EXTEND

13. P-139 PYRAMID Registry

15. Risk of Malignancy, Infection, Serious Infection, and Acute Health Care Use in Patients With Crohnʼs Disease Treated With Adalimumab vs. Immunosuppressants

16. PTU-110 Elevated C reactive protein in anti-TNF-naïve patients is associated with higher remission rates: Abstract PTU-110 Table 1

17. PWE-260 Optimal C reactive protein cut-off point for predicting hospitalisation in patients with moderately active Crohn's disease

18. PTU-109 Efficacy and safety of adalimumab in moderate compared with severe Crohn's disease: pooled data from the charm and extend trials: Abstract PTU-109 Table 1

19. Baseline C-reactive protein is associated with disease progression in patients with Crohnʼs disease

20. Baseline C-Reactive Protein is Associated With Disease Progression in Patients with Crohnʼs Disease

22. Optimal C-Reactive Protein Cutoff Point for Predicting Hospitalization in Patients With Moderately Active Crohn's Disease

Catalog

Books, media, physical & digital resources